Paragon Bioservices Founder Dr. Marco Chacon Elevated to Chairman
Baltimore, MD, February 2, 2016/PR Newswire/ – Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the election of the company’s founder, Dr. Marco Chacon, as Chairman of the Company’s Board of Directors, effective January 26, 2016. Dr. Chacon will focus on the strategic growth of the company and development of key corporate initiatives. Peter Buzy, the President of Paragon, will assume responsibility for day‐to‐day operation of the company.
“I am honored and excited to continue the work that Marco started, and together with our talented and dedicated scientists and associates, build our company on the foundation of expertise and customer commitment that has been established,” said Mr. Buzy. “With Dr. Chacon’s leadership and dedication, Paragon has helped develop and manufacture over fifty different biotherapeutics and vaccines and our vision and strategy is to continue to drive this effort to a new level.”
Dr. Chacon remarked, “I am extremely proud of all that has come to fruition at Paragon over the years, and excited about the future of the company. Responsibility to our clients, a passion for science and our collective need to contribute to better public health—that’s what keeps us motivated and excited about the work that we perform.” Dr. Chacon noted, “We are driven by our commitment to provide exceptional quality, scientific excellence and superior customer service, and I look forward to guiding Paragon toward realizing its full potential.”
About Paragon Bioservices, Inc.
Paragon Bioservices is a private‐equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.
Kevin Sly, SVP Marketing & Commercial Strategy
PH (410) 975‐4053′